Unlock Smarter Lifecycle Strategies for Injectable Therapeutics

As the injectable drug market continues to expand - driven by the rise of biologics, biosimilars, and patient-centric therapies-pharmaceutical companies face increasing pressure to differentiate their products, reduce costs, and optimize delivery systems. One increasingly important strategic lever is the transition between delivery formats, such as moving from traditional vials to prefilled syringes or lyophilized formulations.

This in-depth white paper from Thermo Fisher Scientific (Patheon) explores how changes in delivery format can serve as powerful tools for lifecycle management. Whether the goal is to enhance ease of administration, improve patient safety, extend market exclusivity, or address cold chain limitations, this guide outlines the key technical, regulatory, and operational considerations necessary for a successful format transition.

What You’ll Learn

• How switching formats can reduce costs, simplify logistics, and accelerate time to market
• Regulatory and quality considerations when transitioning from vials to syringes or freeze-dried formats
• The impact of delivery format changes on drug stability, dosing precision, and patient outcomes
• Step-by-step guidance for conducting stability and compatibility testing
• Strategic timing tips to align delivery changes with clinical and commercial milestones
• Common pitfalls and how to avoid delays in development or regulatory approval